Trials / Completed
CompletedNCT01947738
Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)
A Two-Part, Double-Blind, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-891 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Virobay Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Psoriasis is an inflammatory autoimmune disease that might be controlled by a cathepsin S inhibitor like VBY-891.
Detailed description
Refer to Brief Summary
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VBY-891 | Cathepsin S inhibitor |
| DRUG | Placebo |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2013-09-20
- Last updated
- 2013-12-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01947738. Inclusion in this directory is not an endorsement.